Editorial e561 A new chapter in relapsed or refractory multiple myeloma The Lancet Haematology + +... +

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00163-2/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz-8BXI5dJqp9UbGxd2N-SJ1DNI7FvuAF0pwDvCrv3Y9omHb4oI6MHl81QrTlh8A87e-JBIUJmAX4auQwYuCA2ODYV6_6VA&_hsmi=376274862&utm_content=374861330&utm_source=hs_email Editorial e561 A new chapter in relapsed or refractory multiple myeloma The Lancet Haematology https://www.thelancet.com/journals/lanhae/issue/vol12no8/PIIS2352-3026(25)X0008-9 Research landscape of plasma cell disorders in South Asia: a call for collaboration https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00196-6/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz-8RaRKF2c1Lgw4C5Ql8I4tv6RKmiEG_N8BzxH-cu7V_idTx0FSlnLvXM6gY0AyLf-KJfs-zKDC5RWT6NXY0oOb_Ot7uJw&_hsmi=376274862&utm_content=374861330&utm_source=hs_email